Predictive Cardio ZEUS Scientific recently expanded from autoimmune and infectious disease serology into predictive cardiac biomarkers with AccuCardia for inflammation and atherosclerosis risk assessment, presenting a cross-selling opportunity to cardiology and primary care labs seeking advanced cardiovascular risk tools.

Lyme Testing Strength The company has an FDA-cleared Modified Two-Tiered Testing algorithm for Lyme disease that reportedly improves early detection up to 30 percent, creating a compelling upsell to labs and hospitals focusing on infectious disease panels and enhanced Lyme diagnostics.

Integrated Systems Recent product launches like the dIFine 30 System paired with SP30 slide processing indicate a strategy toward integrated immunofluorescence workflows, enabling sales opportunities with labs seeking streamlined automation and end-to-end diagnostic solutions.

Strategic Growth Sebia’s acquisition of ZEUS Scientific in 2022 signals increased financial backing and potential access to broader distribution channels, suggesting expanding opportunities in larger hospital networks and regional laboratories through a more robust corporate portfolio.

Rapid SARS-CoV-2 Interface ZEUS’s 2020 rapid IgM/IgG SARS-CoV-2 test demonstrates capability in rapid, point-in-need infectious disease testing, offering a template for introducing rapid diagnostics and flexible on-site or near-patient testing options to hospitals and urgent care networks.